Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Active, not recruiting
NCT05089734
| Condition | Non-Small Cell Lung Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Gilead Sciences |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 603 participants |
|---|
| Interventions | Sacituzumab Govitecan-hziy (SG), Docetaxel |
|---|
| Start date | Nov 17, 2021 |
|---|
| Completion date | Nov 29, 2023 |
|---|
| Results posted | Jan 14, 2025 |
|---|
Summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
Overall Survival (OS)
Up to 24.4 months · months
| Sacituzumab Govitecan (SG) | 11.1 months |
|---|
| Docetaxel | 9.8 months |
|---|
| p-value | 0.0534 |
|---|
| Hazard Ratio (HR) | 0.84 (95% CI 0.68–1.04) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.